Search Results
Search for other papers by Sumaira Z Hasnain in
Google Scholar
PubMed
Search for other papers by Johannes B Prins in
Google Scholar
PubMed
Search for other papers by Michael A McGuckin in
Google Scholar
PubMed
production and closure of the KIR6.2 K + channel. This in turn leads to the depolarisation and influx of Ca 2 + , which drives the secretion of insulin granules. Insulin secretion is further boosted by incretin-receptor-mediated activation of protein kinase
Search for other papers by Vishal Musale in
Google Scholar
PubMed
Search for other papers by R Charlotte Moffett in
Google Scholar
PubMed
Search for other papers by Bosede Owolabi in
Google Scholar
PubMed
Search for other papers by J Michael Conlon in
Google Scholar
PubMed
Search for other papers by Peter R Flatt in
Google Scholar
PubMed
Search for other papers by Yasser H A Abdel-Wahab in
Google Scholar
PubMed
of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1 . Expert Opinion on Drug Discovery 8 219 – 244 . ( https://doi.org/10.1517/17460441.2013.741580 ) Parthsarathy V Irwin N Hasib A
Department of Metabolism, CIBERDEM, Nutrition and Hormones, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040 Madrid, Spain
Search for other papers by Paola Moreno in
Google Scholar
PubMed
Department of Metabolism, CIBERDEM, Nutrition and Hormones, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040 Madrid, Spain
Search for other papers by Bernardo Nuche-Berenguer in
Google Scholar
PubMed
Department of Metabolism, CIBERDEM, Nutrition and Hormones, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040 Madrid, Spain
Search for other papers by Irene Gutiérrez-Rojas in
Google Scholar
PubMed
Department of Metabolism, CIBERDEM, Nutrition and Hormones, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040 Madrid, Spain
Search for other papers by Alicia Acitores in
Google Scholar
PubMed
Search for other papers by Verónica Sancho in
Google Scholar
PubMed
Department of Metabolism, CIBERDEM, Nutrition and Hormones, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040 Madrid, Spain
Search for other papers by Isabel Valverde in
Google Scholar
PubMed
Department of Metabolism, CIBERDEM, Nutrition and Hormones, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040 Madrid, Spain
Search for other papers by Nieves González in
Google Scholar
PubMed
Department of Metabolism, CIBERDEM, Nutrition and Hormones, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040 Madrid, Spain
Search for other papers by María L Villanueva-Peñacarrillo in
Google Scholar
PubMed
-1 (GLP-1 or GCG as listed in the HUGO database), an incretin hormone with anti-diabetic properties, exerts insulin-like effects upon glucose transport (GT) and metabolism in the liver, skeletal muscle, and fat of humans and rats ( Valverde et al
Search for other papers by Ying Ying in
Google Scholar
PubMed
Search for other papers by Huazhang Zhu in
Google Scholar
PubMed
School of Medicine, Department of Geriatric, Shenzhen University Diabetes Center, Shenzhen University, Shenzhen 518060, China
Search for other papers by Zhen Liang in
Google Scholar
PubMed
Search for other papers by Xiaosong Ma in
Google Scholar
PubMed
Search for other papers by Shiwei Li in
Google Scholar
PubMed
of palmitate-induced cardiomyocyte apoptosis has not been determined thus far. Glucagon-like peptide 1 (GLP1) is an incretin hormone synthesized and secreted by intestinal L-cells and stimulates insulin secretion from pancreatic b-cells in a glucose
Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea
Search for other papers by Jin-Seung Choung in
Google Scholar
PubMed
Search for other papers by Young-Sun Lee in
Google Scholar
PubMed
Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea
Gachon Medical Research Institute, Gil Hospital, Incheon, Republic of Korea
Search for other papers by Hee-Sook Jun in
Google Scholar
PubMed
Introduction Glucagon-like peptide-1 (GLP1) is an incretin hormone that is secreted from enteroendocrine gastrointestinal L cells after meal ( Layer et al . 1995 ). GLP1 controls glucose homeostasis in many organs; it has a glucose
Search for other papers by Rune Ehrenreich Kuhre in
Google Scholar
PubMed
Search for other papers by Nicolai Jacob Wewer Albrechtsen in
Google Scholar
PubMed
Search for other papers by Carolyn Fiona Deacon in
Google Scholar
PubMed
Search for other papers by Emilie Balk-Møller in
Google Scholar
PubMed
Search for other papers by Jens Frederik Rehfeld in
Google Scholar
PubMed
Search for other papers by Frank Reimann in
Google Scholar
PubMed
Search for other papers by Fiona Mary Gribble in
Google Scholar
PubMed
Search for other papers by Jens Juul Holst in
Google Scholar
PubMed
, and is particularly known for its incretin actions , that is, the enhancement of meal-stimulated insulin secretion. This serves to limit postprandial blood glucose levels ( Holst 2007 ), and therefore, GLP-1-based drugs are used to treat type II
Search for other papers by Horng-Yih Ou in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Research Center of Herbal Medicine, Department of Family Medicine, College of Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, 138, Sheng‐Li Road, Tainan 70403, Taiwan
Search for other papers by Hung-Tsung Wu in
Google Scholar
PubMed
Search for other papers by Feng-Hwa Lu in
Google Scholar
PubMed
Search for other papers by Yu-Chu Su in
Google Scholar
PubMed
Search for other papers by Hao-Chang Hung in
Google Scholar
PubMed
Search for other papers by Jin-Shang Wu in
Google Scholar
PubMed
Search for other papers by Yi-Ching Yang in
Google Scholar
PubMed
Search for other papers by Chao-Liang Wu in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Research Center of Herbal Medicine, Department of Family Medicine, College of Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, 138, Sheng‐Li Road, Tainan 70403, Taiwan
Search for other papers by Chih-Jen Chang in
Google Scholar
PubMed
agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion . Life Sciences 94 115 – 121 . ( doi:10.1016/j.lfs.2013.11.010 ). Wang SR Pessah M Infante J Catala D Salvat
Search for other papers by Stacey N Walters in
Google Scholar
PubMed
Search for other papers by Jude Luzuriaga in
Google Scholar
PubMed
Search for other papers by Jeng Yie Chan in
Google Scholar
PubMed
Garvan Institute of Medical Research, St Vincent's Clinical School, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia
Search for other papers by Shane T Grey in
Google Scholar
PubMed
Garvan Institute of Medical Research, St Vincent's Clinical School, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia
Search for other papers by D Ross Laybutt in
Google Scholar
PubMed
receptor, G-protein-coupled receptor 40 ( Gpr40 ( Ffar1 )), and the incretin GLP-1 receptor ( Glp1r ) ( Fig. 3C ). Expression of all the tested β-cell differentiation genes was at least partially restored in islet grafts from diabetic-normalized mice ( Fig
Search for other papers by Thierry Brun in
Google Scholar
PubMed
Search for other papers by Benoit R Gauthier in
Google Scholar
PubMed
). Furthermore, endogenous Pax4 mRNA levels were also induced in human islets by glucose, activin A and betacellulin. In addition, the incretin glucagon-like peptide (GLP)-1, a new therapeutic agent for the treatment of diabetes, which has been shown to increase
Search for other papers by Matthias Laudes in
Google Scholar
PubMed
( Smith 2007 ). However, studies on a potential mechanism whereby TCF7L2 might influence diabetes risk revealed that pathogenetic SNPs are related to impaired insulin secretion and disturbed effects of the incretin system, which suggests that WNT